Device Trial Radar · NCT06003608
Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
51
Actual
Start
Feb 19, 2024
Primary completion
Jan 1, 2025
Study completion Jan 1, 2025
Sponsor
- Lead sponsor
- Nimble Science Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- MRM Health NV
- First posted
- Aug 22, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally and recovered together with the stools (home recovery) together with blood sampling (during the onsite visit).
Conditions
- Parkinson Disease
Interventions
Fluid biopsy capsuleDevice
Ingestion of two SIMBA capsules
Levodopa-Carbidopa Immediate ReleaseDrug
Single dose, Levodopa-Carbidopa Immediate Release
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in microbiome profile of small intestine samples between groupsTime frame: Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.